INTRODUCTION

The COVID-19 pandemic is a serious global health threat that has claimed the lives of more than two million people worldwide. The rapid global spread of the virus has had a devastating socio-economic impact, apart from the disturbance of international health care systems.\(^1\)\(^,\)\(^2\) Current evidence proposes that SARS-CoV-2 is transmitted mainly from person to person through expelled respiratory droplets and less commonly through contact with contaminated surfaces.\(^3\)\(^,\)\(^4\)\(^,\)\(^5\) The viability of this virus on surfaces varies according to their type, demanding frequent surface disinfection and sanitation.\(^6\)\(^,\)\(^7\) In fact, infected individuals are considered contagious 2 days...
before having symptoms and throughout the illness, which draws out the importance of preventing the dissemination of the SARS-CoV-2 infection to mitigate the pandemic.9

Historically, during outbreaks, community pharmacists have been the first point of contact for the provision of health care services, and they played a substantial role in containing viral outbreaks. For example, community pharmacists participated in administering the influenza vaccine during the influenza outbreak in the United States of America (USA) during 2014 and 2015.10 11 During the current COVID-19 pandemic, community pharmacists have also significantly contributed to promoting public health, preventing and managing different medical conditions, ensuring the continuity of patient care and the provision of medications, testing for COVID-19, and advocating for vaccination.12 Moreover, patients with suspected COVID-19 symptoms usually seek medical help from the most easily accessible health care facilities such as community pharmacies.13 Therefore, community pharmacists should be appropriately guided and prepared to triage patients presenting with typical and atypical symptoms of COVID-19.14

However, the pandemic has created a massive burden on community pharmacists since their professional duties were extended. This is accompanied by the increased pressure of searching for alternative medications since patients often practice medications' stockpiling out of fear of drug shortages in some countries.15 16 As providers of pharmaceutical services and free consultations, community pharmacists are being directly exposed to the public, which escalates their risk of acquiring the infection, especially since they are assuming their duties during the lockdown period.17 21 Thus, protective measures should be implemented in pharmacy settings to contain the spread of COVID-19. These procedures include adhering to the protective personal equipment (PPE), frequently disinfecting contact surfaces, and maintaining social distancing. Moreover, community pharmacies should limit the number of clients in the pharmacy, instruct them to wear face masks, screen their temperature before entering, and encounter them through a glass barrier.21 24 In addition, the use of tele-pharmacy care, which includes the provision of consultations, medication order review, and drug information services, should be encouraged to minimize client visits to the pharmacy, to limit the spread of infection.25

The use of dietary supplements for the prevention and treatment of COVID-19 is controversial. Yet recent studies have proven a plausible role of vitamin C, vitamin D, and zinc in preventing acute respiratory tract infections, including COVID-19. These supplements have a safe profile, and their use is warranted among individuals with serum deficiencies and those who are at high risk of acquiring COVID-19.26 30

It is worth mentioning that the preparedness and response of the pharmacists to COVID-19 in the Middle Eastern community has not yet been thoroughly investigated. A simulated-client study from Saudi Arabia has shown that community pharmacies were not well prepared during the onset of the outbreak.31 Hence, the main aim of this study was to gain an insight on the pharmacists' awareness of COVID-19 in the Middle Eastern community, identify the degree of implementing the recommended preventive measures during their daily practice, and to pinpoint the sources of information on which they rely to offer their perceived recommendations to suspected COVID-19 patients.

2 | METHODS

2.1 | Study design

This was an observational cross-sectional study that was conducted during November and December 2020. A self-administered
questionnaire was distributed to community pharmacists informally, as only groups on social media platforms were used. These groups included practicing community pharmacists in Lebanon, Jordan, and Saudi Arabia. The shared link to the questionnaire was posted once daily throughout the study period.

2.2 | Questionnaire development and structure

The questionnaire was revised after it was validated by academics in pharmacy and after being piloted on a sample of 25 pharmacists that were excluded from the total sample. It consisted of four parts: (a) socio-demographic information and pharmacy characteristics (ie, size, number of staff members per shift, number of clients per day, methods of encountering patients, and methods of handling prescriptions); (b) the adopted preventive measures by pharmacists (ie, PPE, hygiene and disinfection practices, frequency of face mask change, the intake of dietary supplements, and previous influenza vaccination) and information about client-directed infection control procedures (ie, limiting the number of clients in the pharmacy, screening clients’ body temperature, and offering free hand sanitizers for patients’ use at the entrance and counter areas); (c) the information resources utilized by the pharmacist and time spent to retrieve COVID-19-related updates; and (d) the perceived recommendations for suspected COVID-19 patients.

2.3 | Data analysis

Completed questionnaires were analyzed by the Statistical Package for the Social Sciences (SPSS®, International Business Machines Corp., Armonk, New York, USA) software version 24. Frequencies and ratios were used for categorical variables and mean ± standard deviation for continuous variables of descriptive data. Also, the Shapiro-Wilk test was used for testing all continuous variables for normality before statistical comparisons. In addition, the association between the degree of preventive measures implemented with the independent variables was tested by Kruskal-Wallis and Mann-Whitney U tests. The significance level was set at P ≤ .05 with a confidence interval (CI) of 95%.

2.4 | The preventive measures score

A score ranging from 0 to 17 was used to count the degree of preventive measures practiced by the community pharmacists, where one mark was counted for each adopted measure of the following: wearing a facemask, frequent handwashing, using sanitizers regularly, disinfecting surfaces and cash, washing white coats frequently, applying a social distancing strategy, avoiding face touch, taking vitamin C, taking zinc, taking vitamin D, receiving this year’s flu vaccine, placing a door sign to instruct patients to wear a facemask prior to entering, posting a door sign to inform patients to alert the staff if they are experiencing COVID-19 symptoms, offering free hand sanitizers for patients’ use, screening patients’ body temperature before entering, limiting the number of clients in the pharmacy, and encountering patients through a physical barrier (either a plexiglass barrier or a dispensing window).

2.5 | Appropriateness of pharmaceutical care

Community pharmacists encountering a patient with typical symptoms of COVID-19 should optimally recommend the patient do a polymerase chain reaction (PCR) test. Pharmacists were asked about the primary perceived recommendation to provide when encountering a patient with a suspected COVID-19 infection. Accordingly, the response was considered appropriate when advising the patient to do a PCR test.

2.6 | Ethical considerations

Guidance from the World Medical Association Declaration of Helsinki was followed in designing and conducting this study. The study protocol was approved by the Institutional Review Board, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan (No. 2020-0833). Pharmacists were requested at the beginning of the study form to approve their participation. The purpose of the study was clearly stated, and they had the right to defer from submitting their response at any time. Confidentiality, anonymity, and non-traceability were strictly maintained.

3 | RESULTS

The study included 800 community pharmacists who participated voluntarily from three Arab countries, of whom 115 (14.4%) were from Saudi Arabia, 424 (53%) from Lebanon, and 261 (32.6%) from Jordan. The estimated numbers of community pharmacists practicing in Lebanon, Jordan, and Saudi Arabia are 3762, 8419, and 8214, respectively. The participants’ socio-demographic information and pharmacy characteristics in the selected countries are presented in Table 1.

Less than half of the pharmacists (354, 44.3%) have reported reading about COVID-19 for less than 15 minutes per day, whereas 251 (31.4%) reported spending 15-30 minutes, 122 (15.3%) reported >0.5-2 hours, and 73 (9%) denied getting any COVID-19 related updates. For the sources of information, the most sought were the websites of health authorities (521, 65.1%), the World Health Organization (456, 57%), and pharmacy colleagues (336, 42%). In addition, social media, TV/radio, the Centers for Disease Control and Prevention (CDC), and the Infectious Disease Society of America website were sought by 312 (39%), 268 (33.5%), 252 (31.5%), and 111 (13.9%), respectively.
**TABLE 1**  Participants’ socio-demographics and pharmacy characteristics among countries (N = 800)

| Factors                      | Total N (%) | Lebanon 424 (53) | Jordan 261 (32.6) | Saudi Arabia 115 (14.4) |
|------------------------------|-------------|-------------------|-------------------|-------------------------|
| Age (y, mean = 32 ± 9.8)     |             |                   |                   |                         |
| 22-30                        | 481 (60.1)  | 303 (63)          | 132 (27.4)        | 46 (9.6)                |
| 31-40                        | 172 (21.5)  | 57 (33.1)         | 81 (47.1)         | 34 (19.8)               |
| 41-50                        | 90 (11.3)   | 34 (37.8)         | 36 (40)           | 20 (22.2)               |
| >50                          | 57 (7.1)    | 30 (52.6)         | 12 (21.1)         | 15 (26.3)               |
| Sex                          |             |                   |                   |                         |
| Male                         | 357 (44.6)  | 126 (35.3)        | 136 (38.1)        | 95 (26.6)               |
| Female                       | 443 (55.4)  | 298 (67.3)        | 125 (28.2)        | 20 (4.5)                |
| Pharmacy ownership           |             |                   |                   |                         |
| Owner                        | 191 (23.9)  | 129 (67.5)        | 51 (26.7)         | 11 (5.8)                |
| Employee                     | 609 (76.1)  | 295 (48.4)        | 210 (34.5)        | 104 (17.1)              |
| Academic degree              |             |                   |                   |                         |
| Bachelor                     | 558 (69.8)  | 303 (54.3)        | 172 (30.8)        | 83 (14.9)               |
| PharmD                       | 148 (18.5)  | 82 (55.4)         | 45 (30.4)         | 21 (14.2)               |
| Masters                      | 84 (10.5)   | 36 (42.9)         | 40 (47.6)         | 8 (9.5)                 |
| PhD                          | 10 (1.3)    | 3 (30)            | 4 (4)             | 3 (3)                   |
| Experience (y, mean = 8.3 ± 8.6) |     |                   |                   |                         |
| <5                           | 397 (49.5)  | 257 (64.7)        | 101 (25.4)        | 39 (9.8)                |
| 5-10                         | 187 (23.4)  | 85 (45.5)         | 83 (44.4)         | 19 (10.2)               |
| 11-15                        | 72 (9)      | 23 (31.9)         | 27 (37.5)         | 22 (30.6)               |
| 16-20                        | 49 (6.1)    | 13 (26.5)         | 22 (44.9)         | 14 (28.6)               |
| >20                          | 95 (11.9)   | 46 (48.4)         | 28 (29.5)         | 21 (22.1)               |
| Pharmacy location            |             |                   |                   |                         |
| City                         | 599 (74.9)  | 272 (45.4)        | 224 (37.4)        | 103 (17.2)              |
| Rural                        | 201 (25.1)  | 152 (75.6)        | 37 (18.4)         | 12 (6)                  |
| Average size of the pharmacy |             |                   |                   |                         |
| Small (32-70 m²)             | 249 (31.1)  | 128 (51.4)        | 93 (37.3)         | 28 (11.2)               |
| Medium (71-100 m²)           | 378 (47.3)  | 198 (52.4)        | 127 (33.6)        | 53 (14)                 |
| Large (>100 m²)              | 173 (21.6)  | 98 (56.6)         | 41 (23.7)         | 34 (19.7)               |
| Number of staff present at the same time per duty shift (mean = 2.4 ± 1.2) |     |                   |                   |                         |
| 1                            | 186 (23.3)  | 124 (66.7)        | 49 (26.3)         | 13 (7)                  |
| 2                            | 315 (39.4)  | 148 (47)          | 128 (40.6)        | 39 (12.4)               |
| 3                            | 163 (20.4)  | 73 (44.8)         | 61 (37.4)         | 29 (17.8)               |
| 4                            | 50 (6.3)    | 17 (34)           | 14 (28)           | 19 (38)                 |
| ≥5                           | 86 (10.8)   | 62 (72.1)         | 9 (10.5)          | 15 (17.4)               |
| Method of encountering patients |          |                   |                   |                         |
| Direct contact (person to person) | 277 (34.6) | 32 (11.6)        | 171 (61.7)        | 74 (26.7)               |
| From behind a plexi-glass barrier | 419 (52.4) | 305 (72.8)       | 74 (17.7)         | 40 (9.5)                |
| Through the dispensing window | 104 (13)   | 87 (83.7)         | 16 (15.4)         | 1 (1)                   |
| Method of handling prescriptions |          |                   |                   |                         |
| Directly from the patient    | 597 (74.6)  | 338 (56.6)        | 156 (26.1)        | 103 (17.3)              |
| Using disposable gloves      | 318 (39.8)  | 99 (31.1)         | 148 (46.5)        | 71 (22.3)               |
| Electronically               | 101 (12.6)  | 13 (12.9)         | 56 (55.4)         | 32 (31.7)               |

(Continues)
Table 2 presents the preventive measures implemented by pharmacists during their duty shifts. Interestingly, although the surveyed community pharmacies belong to the private sector, 72 pharmacies reported receiving governmental support such as PPE, of which 35 (48.6%) were Jordanian, 25 (34.7%) were from Saudi Arabia, and 12 (16.7%) were Lebanese. The most adopted preventive measures by pharmacists included maintaining social distancing (708, 88.5%), avoiding face touch (636, 79.5%), frequent use of sanitizers (691, 86.4%), disinfecting contact surfaces (453, 56.6%), and regular hand washing with soap and water (576, 72%). Most of the participants stated they wore surgical facemasks (626, 78.3%), whereas other types of protectors were less adopted. Eleven pharmacists (1.4%), however, reported not using any PPE. The frequency of changing/washing the facemask among participants varied from once (339, 42.5%), twice (227, 28.4%), to thrice daily (140, 17.5%), while the remaining pharmacists (94, 11.8%) reported using the same facemask for more than a day without changing/washing it, which is against the recommendations. Over one third of the participants took daily vitamin C (42.3%), daily zinc (26.1%), and vitamin D regularly (35.8%).

Although only 240 (30%) pharmacies reported measuring the patient’s body temperature prior to entering the pharmacy, 336 (42%) reported placing a sign requesting the patients having COVID-19 symptoms to alert the pharmacy staff. Also, a total of 672 (84%) pharmacies posted a sign at the entrance requesting the customers to wear facemasks before entering, and a significant number of participants 698 (87.3%) reported providing free hand sanitizers for patients at the entrance and counter areas.

Table 3 summarizes the association between various factors and the score of the preventive measures which were implemented. The mean score was 10.12 ± 2.77 (out of 17), ranging from 2 to 17, where pharmacists in Saudi Arabia have scored the highest (11.03 ± 2.56, P < .001). Female pharmacists were more commonly adhering to the preventive measures than males (10.38 ± 2.68 and 9.8 ± 2.85, respectively, P = .004). Also, pharmacy owners were also more likely to apply more preventive measures than employees (10.66 ± 2.93 and 9.95 ± 2.7, respectively, P = .002), and pharmacists who were older than 40 years were also more devoted to the measures than younger ones (10.79 ± 3.17 and 9.97 ± 2.65, respectively, P = .001). Results have also shown that pharmacies with three or more staff members per duty shift were more commonly adherent than those with one or two pharmacists per shift (10.49 ± 2.55 and 9.90 ± 2.87, respectively, P = .003). In addition, a significant increase in the number of adopted protective measures was noticed in pharmacies with 51-100 clients per day (71.4%) and fabric masks (123, 10.8%). Surgical masks were mostly used in Lebanon (383, 61.2%), while the N-95 mask use was more common in Jordan (139, 57.9%) and infrequent in Lebanon (80, 33.3%). Finally, with regard to social distancing, it was less likely to be practiced in small pharmacies (odds ratio [OR] = 0.57, CI = 0.35-0.92, P = .02).

Pharmacists were asked about the primary action taken when dealing with a suspected COVID-19 patient (Figure 1), for which...
### TABLE 2  Preventive measures adopted by the community pharmacists (N = 800)

| Factors                                                                 | Total N (%)<sup>a</sup> | Lebanon 424 (53)<sup>b</sup> | Jordan 261 (32.6)<sup>b</sup> | Saudi Arabia 115 (14.4)<sup>b</sup> |
|------------------------------------------------------------------------|--------------------------|--------------------------------|-------------------------------|-------------------------------------|
| **Self-directed infection control measures**                           |                          |                                |                               |                                     |
| Personal protective equipment<sup>c</sup>                              |                          |                                |                               |                                     |
| Surgical facemask                                                     | 626 (78.3)               | 383 (61.2)                     | 166 (26.5)                    | 77 (12.3)                           |
| N-95 facemask                                                         | 240 (30)                 | 80 (33.3)                      | 139 (57.9)                    | 21 (8.8)                            |
| Fabric facemask                                                       | 123 (15.4)               | 27 (22)                        | 44 (35.8)                     | 52 (42.3)                           |
| Face shield                                                           | 148 (18.5)               | 84 (56.8)                      | 48 (32.4)                     | 16 (10.8)                           |
| None of the above                                                     | 11 (1.4)                 | 10 (90.9)                      | 1 (9.1)                       | 0 (0)                               |
| **Disinfection and hygiene<sup>c</sup>**                              |                          |                                |                               |                                     |
| Frequent handwashing with soap and water                             | 576 (72)                 | 324 (56.3)                     | 181 (31.4)                    | 71 (12.3)                           |
| Frequent use of sanitizers                                           | 691 (86.4)               | 377 (54.6)                     | 208 (30.1)                    | 106 (15.3)                          |
| Frequent surfaces and cashier area disinfection                       | 453 (56.6)               | 278 (61.4)                     | 107 (23.6)                    | 68 (15)                             |
| Frequent white-coat washing                                          | 298 (37.3)               | 162 (54.4)                     | 72 (24.2)                     | 64 (21.5)                           |
| None of the above                                                     | 16 (2)                   | 5 (31.3)                       | 9 (56.6)                      | 2 (12.5)                            |
| **General preventive measures<sup>c</sup>**                           |                          |                                |                               |                                     |
| Maintaining at least 1.5-m apart from others                          | 708 (88.5)               | 388 (54.8)                     | 216 (30.5)                    | 104 (14.7)                          |
| Avoiding touching eyes, nose, and mouth                              | 636 (79.5)               | 359 (56.4)                     | 193 (30.3)                    | 84 (13.2)                           |
| Taking vitamin C on a daily basis                                     | 338 (42.3)               | 170 (50.3)                     | 114 (33.7)                    | 54 (16)                             |
| Taking zinc on a daily basis                                          | 209 (26.1)               | 81 (38.8)                      | 92 (44)                       | 36 (17.2)                           |
| Taking vitamin D regularly                                           | 286 (35.8)               | 153 (53.5)                     | 89 (31.1)                     | 44 (15.4)                           |
| None of the above                                                     | 9 (1.1)                  | 2 (22.2)                       | 5 (55.6)                      | 2 (22.2)                            |
| **Frequency of facemask change/wash**                                 |                          |                                |                               |                                     |
| Once daily                                                            | 339 (42.5)               | 211 (62.2)                     | 98 (28.9)                     | 30 (8.8)                            |
| Twice daily                                                           | 227 (28.4)               | 133 (58.6)                     | 54 (23.8)                     | 40 (17.6)                           |
| Three times daily                                                     | 140 (17.5)               | 63 (45)                        | 39 (27.9)                     | 38 (27.1)                           |
| Using it for more than 1 d                                           | 94 (11.8)                | 17 (18.1)                      | 70 (74.5)                     | 7 (7.4)                             |
| **Received flu vaccine this year**                                     |                          |                                |                               |                                     |
| No                                                                    | 610 (76.3)               | 337 (55.2)                     | 204 (33.4)                    | 69 (11.3)                           |
| Yes                                                                   | 190 (23.8)               | 87 (45.8)                      | 57 (30)                       | 46 (24.2)                           |
| **Client-directed infection control measures**                         |                          |                                |                               |                                     |
| Presence of a door sign requesting patients to wear facemasks prior to entrance | | | | |
| No                                                                     | 128 (16)                 | 76 (59.4)                      | 52 (40.6)                     | 0 (0)                               |
| Yes                                                                    | 672 (84)                 | 348 (51.8)                     | 209 (31.1)                    | 115 (17.1)                          |
| Presence of a door sign requesting patients to alert the pharmacy staff if they are experiencing COVID-19 symptoms | | | | |
| No                                                                     | 464 (58)                 | 207 (44.6)                     | 184 (39.7)                    | 73 (15.7)                           |
| Yes                                                                    | 336 (42)                 | 217 (64.6)                     | 77 (22.9)                     | 42 (12.5)                           |
| **Pharmacies limiting the number of clients present at one time in the pharmacy** | | | | |
| No                                                                     | 347 (43.4)               | 166 (47.8)                     | 148 (42.7)                    | 33 (9.5)                            |
| Yes                                                                    | 453 (56.6)               | 258 (57)                       | 113 (24.9)                    | 82 (18.1)                           |
| **Measuring the patient’s body temperature before entering**          |                          |                                |                               |                                     |
| No                                                                     | 560 (70)                 | 336 (60)                       | 196 (35)                      | 28 (5)                              |
| Yes                                                                    | 240 (30)                 | 88 (36.7)                      | 65 (27.1)                     | 87 (36.3)                           |
| **Free hand sanitizers at the entrance and counter areas**            |                          |                                |                               |                                     |
| No                                                                     | 102 (12.8)               | 60 (58.8)                      | 37 (36.3)                     | 5 (4.9)                             |
| Yes                                                                    | 698 (87.3)               | 364 (52.1)                     | 224 (32.1)                    | 110 (15.8)                          |

<sup>a</sup>Percentages for the columns.

<sup>b</sup>Percentages for the row.

<sup>c</sup>As multiple responses were given, numbers do add up to 800.
the majority (493, 61.6%) responded that they would recommend performing the PCR test. Lebanese pharmacists (OR = 1.67, CI = 1.21-2.31, P < .001), females (OR = 1.41, CI = 1.06-1.87, P = .02), and young participants aging between 22 and 40 years (OR = 1.65, CI = 1.15-2.37, P = .01) were more likely to provide the most appropriate recommendation. In contrast, participants who work more than 8 hours per day (OR = 0.48, CI = 0.35-0.65, P < .001), and pharmacists who encounter patients directly without a glass barrier (OR = 0.63, CI = 0.47-0.85, P < .001) have provided less appropriate recommendations, such as taking over-the-counter medications. Finally, pharmacists encountering COVID-19 patients during their practice were also more commonly instructing patients to do the PCR test (OR = 1.58, CI = 1.17-2.12, P < .001).

### TABLE 3

The score of implemented preventive measures by pharmacists and its association with different factors (N = 800)

| Factors                              | Score (out of 17) of total implemented preventive measures (mean ± SD) | Mann-Whitney U test | Kruskal-Wallis test | P value |
|--------------------------------------|-----------------------------------------------------------------------|---------------------|---------------------|---------|
| Country                              |                                                                       |                     |                     |         |
| Lebanon                              | 10.52 ± 2.55                                                          |                     |                     | .0001*  |
| Jordan                               | 9.07 ± 2.9                                                            |                     |                     |         |
| Saudi Arabia                         | 11.03 ± 2.56                                                          |                     |                     |         |
| Sex                                  |                                                                       | 69702.5             |                     | .004*   |
| Male                                 | 9.8 ± 2.85                                                            |                     |                     |         |
| Female                               | 10.38 ± 2.68                                                          |                     |                     |         |
| Pharmacy ownership                   |                                                                       | 49615.5             |                     | .002*   |
| Owner                                | 10.66 ± 2.93                                                          |                     |                     |         |
| Employee                             | 9.95 ± 2.7                                                            |                     |                     |         |
| Age (y)                              |                                                                       | 39,630              |                     | .001*   |
| 22-40                                | 9.97 ± 2.65                                                           |                     |                     |         |
| >40                                  | 10.79 ± 3.17                                                          |                     |                     |         |
| Experience                           |                                                                       | 31,700              |                     | .004*   |
| <5 y                                 | 10.2 ± 2.62                                                           |                     |                     |         |
| ≥5 y                                 | 9.45 ± 2.74                                                           |                     |                     |         |
| The average number of clients per day|                                                                       | 39,630              |                     | .001*   |
| ≤50                                  | 9.83 ± 2.85                                                           |                     |                     |         |
| 51-100                               | 10.70 ± 2.50                                                          |                     |                     |         |
| Time spent in pharmacy per day       |                                                                       |                     | 22.32               | <.0001* |
| <5 h                                 | 10.41 ± 2.6                                                           |                     |                     |         |
| 5-8 h                                | 9.76 ± 2.77                                                           |                     |                     |         |
| >8 h                                 | 10.73 ± 2.71                                                          |                     |                     |         |
| The average size of the pharmacy     |                                                                       |                     | 6.61                | .037    |
| Small (32-70 m²)                      | 9.86 ± 2.86                                                           |                     |                     |         |
| Medium                               | 10.11 ± 2.78                                                          |                     |                     |         |
| Large (>100 m²)                       | 10.52 ± 2.59                                                          |                     |                     |         |
| Number of staff present per duty shift|                                                                       | 65,618              |                     | .003*   |
| 1-2                                  | 9.90 ± 2.87                                                           |                     |                     |         |
| ≥3                                   | 10.49 ± 2.55                                                          |                     |                     |         |
| Time spent per day to retrieve information about COVID-19 | | 31499.5 | | <.0001* |
| ≤30 min                              | 9.95 ± 2.73                                                           |                     |                     |         |
| >30 min                              | 11.06 ± 2.82                                                          |                     |                     |         |
| COVID-19 patients encountered during practice | | 47,348 | | .40 |
| No                                   | 10.26 ± 2.88                                                          |                     |                     |         |
| Yes                                  | 10.09 ± 2.75                                                          |                     |                     |         |

*Statistically significant (P ≤ .05).
on governmental websites, which is considered as a good indicator of the trust in national health care systems in these countries.

Although pharmacists in Saudi Arabia have significantly scored higher than the other countries regarding adherence to infection preventive measures, the overall score for the three countries was generally slightly higher than the average score for the scale used. This indicates that most community pharmacies in these countries did not undertake sufficient protective actions to protect pharmacy staff and customers from COVID-19. This was supported by a recent study from Saudi Arabia, where social distancing, wearing facial masks, and other protective measures were violated by community pharmacies despite the strict directives from the government.\textsuperscript{31} It is essential to distinguish the several challenges that act as barriers restraining the adoption of precautionary measures. Even though these challenges do not apply to Saudi Arabia, they may include the absence of effective national policies, the lack of resources and funds including the high cost of applying the measures, and the declined income of pharmacists in Jordan and Lebanon.\textsuperscript{36,41} However, pharmacists should recognize that these measures provide a safe environment for staff and customers and ensure the continuity of their role in addressing the current global health crisis.\textsuperscript{36} It was also found, in the current study, that pharmacists older than 40 years were significantly more adherent to the measures than younger ones. This might be due to the fact that age increases the risk for severe illness from COVID-19 (eg, hospitalization, intensive care unit admission, ventilator requirement, or death).\textsuperscript{42}

When encountering patients with typical COVID-19 symptoms, performing a PCR test was mostly recommended by both Lebanese and Jordanian pharmacists. This could be explained by the larger percentage of pharmacists encountering such patients in both countries compared with Saudi Arabia. On the other hand, in the latter country, community awareness of this test is high because it is widely and freely available for the public, and anyone can set an online appointment for it anytime (usually through the smartphone application).\textsuperscript{43} It was also found that participants who worked more than 8 hours, and those who encountered many clients per day, were providing inappropriate recommendations. This might be due to the work overload, exhaustion, and stress during the lockdown period, which can be diminished by having enough personnel to divide the required tasks.

Finally, our current study is associated with some limitations. A self-administered online questionnaire was used to collect the data, which would probably demonstrate results that do not reflect the actual behavior of pharmacists. However, this was found as the most convenient method available for data collection during the pandemic. Another potential limitation to this non-probability sampling method is that our findings may not be extrapolated to all Arab countries in the Middle East, where national regulations and pharmacy practice during the COVID-19 outbreak may vary from one country to another. Also, it is worth noting that this study was conducted when the outbreak was at its peak in the Middle East, when community pharmacies were targets for pharmaceutical care due to the fear

\section*{4 | DISCUSSION}

On November 13, 2020, the CDC issued a guiding statement for community pharmacists and pharmacy technicians to appropriately respond to COVID-19. This guidance displays the recommended strategies and preventive measures to tackle COVID-19 that should be implemented into pharmacy operations to minimize the occupational risk of exposure to SARS-CoV-2 and to reduce the risk of patients and staff acquiring the infection.\textsuperscript{21} Besides, applying adequate and sufficient practices improves the patients’ and health professionals’ perception of the pharmacy profession.\textsuperscript{36}

Since the onset of the outbreak, community pharmacists have been involved not only in the provision of medications and COVID-19 preventive supplies and medical equipment supplies, but also in raising public awareness and education about COVID-19.\textsuperscript{36} For the latter to be attained, the pharmacist should have solid background information on COVID-19. In this study, the greater proportion of community pharmacists spent less than 15 minutes per day to obtain information about COVID-19, which might be due to their overwhelming duties, particularly during the lockdown period. In fact, this might affect the quality, precision, and accuracy of information provided to the public, which is essential for combating COVID-19.\textsuperscript{27} Interestingly, more than 73\% of the community pharmacists relied on traditional media and social network platforms as a source of information about COVID-19. This finding corroborates recent studies about COVID-19-related information among pharmacists and exhibits the importance of the social network and traditional mass media in information delivery.\textsuperscript{38,39}

However, pharmacists need to rely on professional and official medical information to acquire adequate knowledge about COVID-19 that supports them in educating the public without spreading incorrect and misleading information. In Taiwan, for example, health care providers have received COVID-19 updates through formal training sessions. This method has not only provided reliable information to the health care providers but also enhanced their self-confidence when forwarding the information to the community.\textsuperscript{38} On the other hand, health care providers in China, who were not guided and exposed to COVID-19 information in a proper way, had higher levels of anxiety and depression.\textsuperscript{40} In our study, it was evident that pharmacists in Saudi Arabia and Jordan are significantly relying...
of visiting hospitals. This overload on community pharmacists may have greatly affected their responses.

5 | CONCLUSION

Within this study, the performance of community pharmacies in Jordan, Saudi Arabia, and Lebanon during the COVID-19 outbreak was inadequate regarding the application of infection prevention measures. Health authorities in these countries are advised to strengthen surveillance and monitoring activities to ensure better adherence to the regulations. Furthermore, simulated-patient research to evaluate the actual behavior of community pharmacists and the extent to which they are implementing the infection control measures are highly recommended.

ACKNOWLEDGMENT

The authors would like to thank Mr Donald W. Flood for proofreading the manuscript and Ms Nawal Kais for her contribution in the data collection.

DISCLOSURE

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

The dataset presented in this article is available only upon reasonable request, since it contains confidential information. Requests to access the datasets should be directed to the first author (r.itani@bau.edu.lb).

ORCID

Rania Itani https://orcid.org/0000-0003-4316-3224
Samar Karout https://orcid.org/0000-0002-4750-6434
Hani M. J. Khojah https://orcid.org/0000-0002-0586-1526
Tareq L. Mukattash https://orcid.org/0000-0003-0200-9845

REFERENCES

1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronavirus. J Adv Res. 2020;24:91-98.
2. Liu Y-C, Kuo R-L, Shih S-R. COVID-19: the first documented coronavirus pandemic in history. Biomed J. 2020;43:328-333.
3. Centers for Disease Control and Prevention. Coronavirus (COVID-19) frequently asked questions [Internet]. CDC; 2021. https://www.cdc.gov/coronavirus/2019-ncov/faq.html. Accessed November 22, 2020.
4. World Health Organization. Coronavirus disease (COVID-19): How is it transmitted? [Internet]. WHO; 2020. https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-how-is-it-transmitted. Accessed November 22, 2020.
5. Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New microb.. Infect. 2020;35:100679.
6. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382:1564-1567.
7. Nazario B. Coronavirus and Surfaces: How Long Does COVID-19 Live on Surfaces? [Internet]. WebMD; 2021. https://www.webmd.com/lung/how-long-covid-19-lives-on-surfaces. Accessed February 18, 2021.
8. Ken P. New coronavirus stable for hours on surfaces | National Institutes of Health (NIH) [Internet]. National Institutes of Health; 2020. https://www.nih.gov/news-events/news-releases/new-coronavirus-stable-hours-surfaces. Accessed November 28, 2020.
9. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577-582.
10. Guerci J, Campbell CT, Curtis SD. The pharmacists’ role in disease outbreaks: navigating the dynamics of uncertainty before, during, and after disease outbreaks. J Pediatric Pharmacol Ther. 2020;25:384-389.
11. Li H, Zheng S, Liu F, Liu W, Zhao R. Fighting against COVID-19: Innovative strategies for clinical pharmacists. Res Soc Adm Pharm. 2021;17:1813-1818.
12. Strand MA, Bratberg J, Eukel H, Hardy M, Williams C. Community pharmacists’ contributions to disease management during the COVID-19 pandemic. Prev Chronic Dis. 2020;17:98.
13. Karasneh R, Al-Azzam S, Muflih S, Soudah O, Hawamdeh S, Khader Y. Media’s effect on shaping knowledge, awareness risk perceptions and communication practices of pandemic COVID-19 among pharmacists. Res Soc Adm Pharm. 2021;17:1897-1902.
14. Liu S, Luo P, Tang M, et al. Providing pharmacy services during the coronavirus pandemic. Int J Clin Pharm. 2020;42:299-304.
15. Elbeddini A, Prabaharan T, Almasalkhi S, Tran C. Pharmacists and COVID-19. J Pharm Policy Pract. 2020;13:1-4.
16. Parkhurst C, Singh Purewal G, Donyai P. Community pharmacy and COVID-19-the unsung heroes on our high streets. J patient Exp. 2020;7:282-284.
17. Amariles P, Ledezma-Morales M, Salazar-Ospina A, Hincapié-Garcia JA. How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal. Res Soc Administrative Pharm. 2021;17:1988-1989.
18. Mukattash TL, Jarab AS, Mukattash I, et al. Pharmacists’ perception of their role during covid-19: A qualitative content analysis of posts on facebook pharmacy groups in jordan. Pharm Pract (Granada). 2020;18:1-6.
19. Ung COL. Community pharmacist in public health emergencies: quick to action against the coronavirus 2019-nCoV outbreak. Res Soc Adm Pharm. 2020;16:583-586.
20. Lau H, Khosrawipour V, Kocbach P, et al. The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. J Travel Med. 2020;27:taa037.
21. Centers for Disease Control and Prevention. Guidance for Pharmacies [Internet]. CDC; 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/pharmacies.html. Accessed December 30, 2020.
22. Zaïdi STR, Hasan SS. Personal protective practices and pharmacy services delivery by community pharmacists during COVID-19 pandemic: results from a national survey. Res Soc Adm Pharm. 2021;17:1832-1837.
23. Sum ZZ, Ow C.J.W. Community pharmacy response to infection control during COVID-19, a cross-sectional survey. Res Soc Adm Pharm. 2021;17:1845-1852.
24. New South Wales Ministry of Health. Advice for community pharmacies on COVID-19 - COVID-19 (Coronavirus) [Internet]. New South Wales Government, Australia; 2020. https://www.health.nsw.gov.au/Infectious/covid-19/Pages/pharmacy.aspx. Accessed January 15, 2021.
25. Koster ES, Philibert D, Bouvy ML. Impact of the COVID-19 epidemic on the provision of pharmaceutical care in community pharmacies. Res Soc Adm Pharm. 2021;17:2002-2004.
26. Mercola J, Grant WB, Wagner CL. Evidence regarding vitamin D and risk of COVID-19 and its severity. *Nutrients*. 2020;12:3361.
27. Bae M, Kim H. Mini-review on the roles of vitamin C, vitamin D, and selenium in the immune system against COVID-19. *Molecules*. 2020;25:5346.
28. Skalny AV, Rink L, Ajsuvakova OP, et al. Zinc and respiratory tract infections: perspectives for COVID-19 (Review). *Int J Mol Med*. 2020;46:17-26.
29. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. *J Infect Public Health*. 2020;13:1373-1380.
30. Carr AC, Rowe S. The emerging role of vitamin C in the prevention and treatment of COVID-19. *Nutrients*. 2020;12:3286.
31. Khojah HMJ. Community pharmacy services and preparedness during COVID-19 outbreak in Madinah, Saudi Arabia. *Saudi Pharm J*. 2020;28:1402-1407.
32. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2 (COVID-19) [Internet]. CDC; 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html. Accessed January 28, 2021.
33. Sacre H, Obeid S, Choueiry G, et al. Factors associated with quality of life among community pharmacists in Lebanon: results of a cross-sectional study. *Pharm Pract (Granada)*. 2019;17:1613.
34. AlRuthia Y, Alsenaidy MA, Alrabiah HK, AlMuhaisen A, Alshehri M. The status of licensed pharmacy workforce in Saudi Arabia: a 2030 economic vision perspective. *Hum Resour Health*. 2018;16:28.
35. Abu Asab MIEA, Abushams L, Alsoul-Younes A, Wazaify M, "A decade in leaps and bounds": pharmacy in Jordan-revisited. *Jordan J Pharm Sci*. 2019;12:51-61.
36. Hoti K, Jakupi A, Hetemi D, Raka D, Hughes J, Desselle S. Provision of community pharmacy services during COVID-19 pandemic: a cross sectional study of community pharmacists’ experiences with preventative measures and sources of information. *Int J Clin Pharm*. 2020;42:1197-1206.
37. Wang P-W, Lu W-H, Ko N-Y, et al. COVID-19-related information sources and the relationship with confidence in people coping with COVID-19: facebook survey study in Taiwan. *J Med Internet Res*. 2020;22:e20021.
38. Tesfaye ZT, Yismaw MB, Negash Z, Ayele AG. COVID-19-related knowledge, attitude and practice among hospital and community pharmacists in Addis Ababa, Ethiopia. *Integr Pharm Res Pract*. 2020;9:105-112.
39. Bhagavathula AS, Alhdalee WA, Rahmani J, Mahabadi MA, Bandari DK. Knowledge and perceptions of COVID-19 among health care workers: cross-sectional study. *JMIR Public Health Surveill*. 2020;6:19160.
40. Xing L-Q, Xu M-L, Sun J, et al. Anxiety and depression in frontline health care workers during the outbreak of Covid-19. *Int J Soc Psychiatry*. 2020;1-8.
41. Maqbool A, Khan NZ. Analyzing barriers for implementation of public health and social measures to prevent the transmission of COVID-19 disease using DEMATEL method. *Diabetes Metab Syndr*. 2020;14:887-892.
42. Centers for Disease Control and Prevention. Older Adults and COVID-19 [Internet]. CDC; 2021. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html. Accessed January 28, 2021.
43. Saudi Ministry of Health. Public Health – Expanded Testing [Internet]. https://www.moh.gov.sa/en/HealthAwareness/EducationalContent/PublicHealth/Pages/Expanded_Testing.aspx. Accessed January 15, 2021.

How to cite this article: Itani R, Karout S, Khojah HMJ, et al. Community pharmacists’ preparedness and responses to COVID-19 pandemic: A multinational study. *Int J Clin Pract*. 2021;00:e14421. https://doi.org/10.1111/ijcp.14421